Table 5.
Summary of demography and medication differences between participants treated with olanzapine monotherapy bearing the rs2011425 non-G allele and G allele
| rs2011425 T/T | rs2011425 G/T, G/G | P | |
|---|---|---|---|
| Age (years) | 51.77 ± 15.26 | 44.33 ± 14.08 | 0.064 |
| Sex (male/female) | 7/11 | 32/41 | 0.704 |
| Smoking (Nonsmoker/smoker) | 17/1 | 67/6 | 0.704 |
| BMI (kg/m2) | 24.12 ± 4.53 | 23.60 ± 5.29 | 0.675 |
| PANSS total score | 72.30 ± 16.75 | 71.61 ± 12.85 | 0.871 |
| Disease duration (years) | 19.86 ± 13.31 | 17.83 ± 14.83 | 0.574 |
| CPZeqa (mg/day) | 490.41 ± 245.61 | 494.44 ± 260.03 | 0.951 |
| BPDeqb (mg/day) | 0.81 ± 1.86 | 0.67 ± 1.57 | 0.766 |
| DZPeqc (mg/day) | 7.97 ± 14.30 | 6.19 ± 9.19 | 0.953 |
Data are presented as mean ± standard deviation values
BMI Body mass index, PANSS Positive and Negative Syndrome Scale
aThe daily dosages of antipsychotic drugs were converted to approximate chlorpromazine equivalents
bThe daily dosages of anticholinergic antiparkinsonian drugs were converted to approximate biperiden equivalents
cThe daily dosages of benzodiazepine were converted to approximate diazepam equivalents